Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy

2002 ◽  
Vol 1 (1) ◽  
pp. 8
Author(s):  
Richard van der Linden ◽  
Chris Bangma ◽  
Albert Osterhaus ◽  
Bart Haagmans
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
T Cell ◽  
Cancer Patients ◽  
T Cell Responses ◽  
Cell Responses

Analysis of PSA-Specific T-Cell Responses of Prostate Cancer Patients Given a PSA-Based Vaccine on a Clinical Trial

2003 ◽  
Author(s):  
James Gulley ◽  
William Dahut ◽  
Philip M. Arlen ◽  
Kwong Tsang ◽  
Jeffrey Schlom
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
T Cell ◽  
Cancer Patients ◽  
T Cell Responses ◽  
Cell Responses

scholarly journals Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients

2011 ◽  
Vol 61 (2) ◽  
pp. 169-179 ◽  
Author(s):  
Ray Wilkinson ◽  
Katherine Woods ◽  
Rachael D’Rozario ◽  
Rebecca Prue ◽  
Frank Vari ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
Signal Peptide ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Healthy Donors ◽  
Kallikrein 4 ◽  
Cytotoxic T Cell Responses

RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1805-1805
Author(s):  
Gunnar Kvalheim ◽  
Steinar Aamdal ◽  
Gustav Gaudernack
Keyword(s):  
Prostate Cancer ◽  
T Cell ◽  
Malignant Melanoma ◽  
Cancer Patients ◽  
Ex Vivo ◽  
T Cell Responses ◽  
T Cell Response ◽  
Patient Specific ◽  
Cell Responses ◽  
Melanoma Patients

Abstract Anti-tumour vaccines targeting the entire tumour antigen repertoire represent an attractive immunotherapeutic approach. This repertoire is present in the total mRNA isolated from the tumour. The mRNA from each cancer patient may be amplified and thus overcome the problem of limitation of material that has hampered the development of individualized vaccines. We have developed immuno-gene-therapy for malignant melanoma and prostate cancer. Monocyte-derived dendritic dells are transfected with autologous melanoma-mRNA or mRNA from three prostate cancer cell lines (DU-145, LN-CaP and PC-3). The vaccines may generate T cell responses against a broad repertoire of tumor-associated epitopes, and the melanoma approach moreover target patient-specific tumor antigens. Effective protocols were established for mRNA-transfection by square wave electroporation and for generation of clinical grade dendritic cells. A full scale preclinical evaluation demonstrated in vitro T cell responses in 6/6 advanced melanoma patients. The responses were specific to antigens encoded by the transfected tumor-mRNA. Recently, we have conducted two phase I/II trials, in advanced malignant melanoma and androgen-resistant prostate cancer. Successful vaccine preparations were obtained for all 41 patients elected. No serious adverse effects were observed. Specific T cell responses (T cell proliferation and/or IFNγ ELISPOT) were demonstrated in 9/19 evaluable melanoma patients and in 12/19 prostate cancer patients. The response rates were higher for patients receiving intradermal vaccination, compared to intranodal injection. Thirteen prostate cancer patients developed a decrease in log-slope PSA. The PSA-response was significantly related to the T cell response (p=0,002). We conclude that the tumour mRNA based DC-vaccine is feasible and safe, and that T cell responses are elicited in about 50% of patients. In the next generation clinical protocols, patients will undergo Treg depletion by chemotherapy (Temozolomide) prior to DC vaccination. Subsequently, T cells will be expanded ex vivo using the Dynabeads Clin Ex Vivo system before re-infusion into the patients.

scholarly journals 1075: Enhanced Systemic T-Cell Responses following Combination in Situ Gene Therapy + Radiotherapy or Hormonal Therapy for Prostate Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 283-284
Author(s):  
Takefumi Satoh ◽  
Bin S. Teh ◽  
Terry L. Timme ◽  
Wei-Yuan Mai ◽  
Maria T. Vlachaki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
T Cell ◽  
Hormonal Therapy ◽  
T Cell Responses ◽  
Cell Responses

UP-02.085 Antigen-Specific T-Cell Responses Against Tumor-Antigens Are Controlled by Regulatory T-Cells in Prostate Cancer Patients

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S289
Author(s):  
B. Hadaschik ◽  
Y. Su ◽  
E. Hadaschik ◽  
M. Hohenfellner ◽  
P. Beckhove
Keyword(s):  
Prostate Cancer ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Tumor Antigens ◽  
T Cell Responses ◽  
Cell Responses

889 ANTIGEN-SPECIFIC T CELL RESPONSES AGAINST TUMOR-ANTIGENS ARE CONTROLLED BY REGULATORY T CELLS IN PROSTATE CANCER PATIENTS

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Boris Hadaschik ◽  
Yun Su ◽  
Eva Hadaschik ◽  
Markus Hohenfellner ◽  
Philipp Beckhove
Keyword(s):  
Prostate Cancer ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Tumor Antigens ◽  
T Cell Responses ◽  
Cell Responses

scholarly journals High-titer lentiviral vectors stimulate fetal calf serum-specific human CD4 T-cell responses: implications in human gene therapy

Gene Therapy ◽  
2009 ◽  
Vol 16 (6) ◽  
pp. 788-795 ◽  
Author(s):  
L Bao ◽  
H Guo ◽  
X Huang ◽  
S Tammana ◽  
M Wong ◽  
...  
Keyword(s):  
Gene Therapy ◽  
T Cell ◽  
Fetal Calf Serum ◽  
Human Gene ◽  
High Titer ◽  
Calf Serum ◽  
T Cell Responses ◽  
Cd4 T Cell ◽  
Human Gene Therapy ◽  
Cell Responses
Sign in / Sign up

Export Citation Format

Share Document